BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-123@catalystbrief.girapphe.com
DTSTAMP:20261117T181556Z
LAST-MODIFIED:20261117T181556Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: Gilead Sciences — Sacituzumab Govitecan-hziy [Feb 2027]
DESCRIPTION:Phase 3 primary completion: Study of Sacituzumab Govitecan-hziy
  and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizuma
 b in Patients With Previously Untreated\, Locally Advanced Inoperable or M
 etastatic Triple-Negative Breast Cancer.\nSource: https://clinicaltrials.g
 ov/study/NCT05382286\nhttps://catalystbrief.girapphe.com/e/123?lang=en\nNo
 t investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/123?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
